BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kantor S, Mochizuki T, Lops SN, Ko B, Clain E, Clark E, Yamamoto M, Scammell TE. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 2013;36:1129-38. [PMID: 23904672 DOI: 10.5665/sleep.2870] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Demidova A, Kahl E, Fendt M. Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110517] [Reference Citation Analysis]
2 Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
3 Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 2014;8:57. [PMID: 24834023 DOI: 10.3389/fnins.2014.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
4 Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019;12:1756286419875622. [PMID: 31632459 DOI: 10.1177/1756286419875622] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
5 Khalil R, Fendt M. Increased anxiety but normal fear and safety learning in orexin-deficient mice. Behavioural Brain Research 2017;320:210-8. [DOI: 10.1016/j.bbr.2016.12.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
6 Rogers AA, Aiani LM, Blanpain LT, Yuxian S, Moore R, Willie JT. Deep brain stimulation of hypothalamus for narcolepsy-cataplexy in mice. Brain Stimul 2020;13:1305-16. [PMID: 32320748 DOI: 10.1016/j.brs.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
8 Weymann KB, Wood LJ, Zhu X, Marks DL. A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain Behav Immun 2014;37:84-94. [PMID: 24216337 DOI: 10.1016/j.bbi.2013.11.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
9 Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy—clinical aspects, pathophysiology and management strategy. Nat Rev Neurol 2014;10:386-95. [DOI: 10.1038/nrneurol.2014.97] [Cited by in Crossref: 103] [Cited by in F6Publishing: 77] [Article Influence: 12.9] [Reference Citation Analysis]
10 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
11 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kroeger D, Ferrari LL, Petit G, Mahoney CE, Fuller PM, Arrigoni E, Scammell TE. Cholinergic, Glutamatergic, and GABAergic Neurons of the Pedunculopontine Tegmental Nucleus Have Distinct Effects on Sleep/Wake Behavior in Mice. J Neurosci 2017;37:1352-66. [PMID: 28039375 DOI: 10.1523/JNEUROSCI.1405-16.2016] [Cited by in Crossref: 90] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
13 Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol 2016;18. [DOI: 10.1007/s11940-016-0429-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
14 Black SW, Sun JD, Santiago P, Laihsu A, Kimura N, Yamanaka A, Bersot R, Humphries PS. Partial ablation of the orexin field induces a sub-narcoleptic phenotype in a conditional mouse model of orexin neurodegeneration. Sleep 2018;41. [DOI: 10.1093/sleep/zsy116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Shiromani PJ, Peever JH. New Neuroscience Tools That Are Identifying the Sleep-Wake Circuit. Sleep 2017;40. [PMID: 28329204 DOI: 10.1093/sleep/zsx032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
16 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Dang R, Chen Q, Song J, He C, Zhang J, Xia J, Hu Z. Orexin knockout mice exhibit impaired spatial working memory. Neurosci Lett 2018;668:92-7. [PMID: 29325715 DOI: 10.1016/j.neulet.2018.01.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
18 Erickson ETM, Ferrari LL, Gompf HS, Anaclet C. Differential Role of Pontomedullary Glutamatergic Neuronal Populations in Sleep-Wake Control. Front Neurosci 2019;13:755. [PMID: 31417341 DOI: 10.3389/fnins.2019.00755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Barateau L, Liblau R, Peyron C, Dauvilliers Y. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. CNS Drugs 2017;31:821-34. [DOI: 10.1007/s40263-017-0464-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
20 Thorpy MJ. Update on Therapy for Narcolepsy. Curr Treat Options Neurol 2015;17. [DOI: 10.1007/s11940-015-0347-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
21 Liu M, Blanco-Centurion C, Shiromani PJ. Rewiring brain circuits to block cataplexy in murine models of narcolepsy. Curr Opin Neurobiol 2017;44:110-5. [PMID: 28445807 DOI: 10.1016/j.conb.2017.03.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Brown JA, Woodworth HL, Leinninger GM. To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance. Front Syst Neurosci 2015;9:9. [PMID: 25741247 DOI: 10.3389/fnsys.2015.00009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
23 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
24 Mavanji V, Butterick TA, Duffy CM, Nixon JP, Billington CJ, Kotz CM. Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiol Learn Mem 2017;146:21-30. [PMID: 29107703 DOI: 10.1016/j.nlm.2017.10.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
25 Gao XB, Hermes G. Neural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animals. Front Syst Neurosci 2015;9:142. [PMID: 26539086 DOI: 10.3389/fnsys.2015.00142] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
26 Mayer G, Bassetti CL, Dauvilliers Y. Treatment options in narcolepsy. Expert Opinion on Orphan Drugs 2013;1:987-99. [DOI: 10.1517/21678707.2013.854701] [Reference Citation Analysis]
27 Barateau L, Lopez R, Dauvilliers Y. Treatment Options for Narcolepsy. CNS Drugs 2016;30:369-79. [PMID: 27155860 DOI: 10.1007/s40263-016-0337-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
28 Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z. Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target. Curr Pharm Des 2019;25:4208-20. [PMID: 31663471 DOI: 10.2174/1381612825666191029101830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Mahoney CE, Agostinelli LJ, Brooks JN, Lowell BB, Scammell TE. GABAergic Neurons of the Central Amygdala Promote Cataplexy. J Neurosci 2017;37:3995-4006. [PMID: 28235898 DOI: 10.1523/JNEUROSCI.4065-15.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
30 Bastianini S, Berteotti C, Gabrielli A, Del Vecchio F, Amici R, Alexandre C, Scammell TE, Gazea M, Kimura M, Lo Martire V, Silvani A, Zoccoli G. SCOPRISM: A new algorithm for automatic sleep scoring in mice. Journal of Neuroscience Methods 2014;235:277-84. [DOI: 10.1016/j.jneumeth.2014.07.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]